Exploring the efficacy of AMACR, ERG, and AR immunostains in prostatic adenocarcinoma and their association with novel grade groups
European Journal of Histochemistry · 2025
DOI: 10.4081/ejh.2025.4172 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Histochemistry, 2025. Verfasst von Mohamed O Andarawi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pathology Department, College of Medicine, King Khalid University, Abha. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Transcriptional Regulator ERG, Adenocarcinoma, Racemases and Epimerases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The study examines the utility of AMACR, ERG, and AR immunostains in diagnosing prostatic adenocarcinoma (PCa) and assessing prognosis in comparison to the Gleason score and new WHO grading groups. Seventeen PCa biopsies and five benign prostatic hyperplasia (BPH) biopsies were analyzed. Immunoreactivity, scored from 1 to 3 based on percentage of positive cells and intensity of expression, was assessed, revealing 76.47% positivity for AMACR, 35.29% for ERG, and 94.12% for AR in PCa cases, with variable scores and intensity among markers and grade groups. AMACR sensitivity and ERG specificity were noted. Higher-grade PCa exhibited increased positivity for both markers, indicating prognostic significance. In BPH cases, AMACR showed positivity in 2 cases, ERG in 1, and AR in all cases, albeit with lower expression. Differential expression was observed among immunomarkers and grade groups of malignancy. AMACR and ERG stains serve as sensitive and specific markers for PCa diagnosis and prognosis. Their increasing positivity with higher-grade groups underscores prognostic value. These findings highlight the importance of immunostains in refining PCa diagnosis and prognostication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pathology Department, College of Medicine, King Khalid University, Abha.
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha.
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Najran University.
- Clinical Laboratory Sciences Department, College of Applied Medical Sciences, Jouf University, Sakaka.
- Department of Medical Laboratory Sciences, College of Health Sciences, Gulf Medical University, Ajman.
- Department of Medical Laboratory Technology, College of Applied Medical Sciences, Northern Border University, Arar.
ORCID-Profile: Mohamed O Andarawi, Adil A Yousif, Elryah I Ali
Zitieren
APA
Andarawi, M. O., Otifi, H., Hassan, H., Yousif, A. A., Mustafa, S. A., Elsiddig, S. A., Babker, A. M., Ali, E. I., & Elhag, O. O. (2025). Exploring the efficacy of AMACR, ERG, and AR immunostains in prostatic adenocarcinoma and their association with novel grade groups. European Journal of Histochemistry. https://doi.org/10.4081/ejh.2025.4172
Vancouver
Andarawi MO, Otifi H, Hassan H, Yousif AA, Mustafa SA, Elsiddig SA, et al. Exploring the efficacy of AMACR, ERG, and AR immunostains in prostatic adenocarcinoma and their association with novel grade groups. European Journal of Histochemistry. 2025. doi:10.4081/ejh.2025.4172
BibTeX
@article{Andarawi2025,
author = {Andarawi, Mohamed O and Otifi, Hassan and Hassan, Hesham and Yousif, Adil A and Mustafa, Saadalnour A and Elsiddig, Shawgi A and Babker, Asad Ma and Ali, Elryah I and Elhag, Omer Osman},
title = {Exploring the efficacy of AMACR, ERG, and AR immunostains in prostatic adenocarcinoma and their association with novel grade groups},
journal = {European Journal of Histochemistry},
year = {2025},
doi = {10.4081/ejh.2025.4172}
}
EUVIMED